Pheton Holdings Ltd

Pheton Holdings Ltd is a healthcare solutions provider that specializes in the development and commercialization of treatment planning software and devices for brachytherapy. Brachytherapy is a form of targeted radiation therapy used in cancer treatment, where radioactive sources are placed inside the patient to kill cancer cells and shrink tumors. The company's proprietary treatment planning system, FTTPS (Feitian Treatment Planning System), is designed to assist medical professionals in determining target volumes, prescription doses, and dose limitations to protect organs at risk, while generating dose distribution plans for cancer patients with various malignant tumors. Founded in 1998, Pheton Holdings Ltd operates through its wholly owned operating subsidiary, Beijing Feitian Zhaoye Technology Co., Ltd., and is headquartered in Beijing, China. The company's Class A ordinary shares began trading on the Nasdaq Capital Market under the symbol "PTHL" following its initial public offering in September 2024. Pheton Holdings aims to establish a potential new standard of care across multiple malignant tumor applications. The company has also expanded its portfolio through the acquisition of a 51% stake in iTonic Corporation, a U.S.-based integrated home health AI firm. In January 2026, Pheton Holdings Ltd announced its rebranding to iTonic Holdings Ltd and a change of its Nasdaq ticker symbol to "ITOC". Sources: [1] https://wealthyhood.com/en/stocks/pthl.nasdaq/ [2] https://www.stocktitan.net/overview/PTHL/ [3] https://www.perplexity.ai/finance/PTHL [4] https://www.marketbeat.com/stocks/NASDAQ/PTHL/ [5] https://www.bitget.com/wiki/pthl-stock [6] https://www.nasdaq.com/press-release/pheton-holdings-ltd-announces-closing-initial-public-offering-2024-09-06 [7] https://www.tipranks.com/news/company-announcements/pheton-holdings-to-rebrand-as-itonic-holdings-and-change-nasdaq-ticker-to-itoc